← Markets

Novavax, Inc.

NVAX · NASDAQ

Market closed$8.21$-0.030000 (-0.36%)After hours $8.15 · -0.73%

Key statistics

Previous close$8.24
Open$8.13
Day high$8.29
Day low$8.06
52-week high$11.97
52-week low$6.20
Market cap1.35B
Volume2.18M
Average volume4.84M
P/E ratio164.20
Forward P/E—
EPS0.05
Dividend yield0.00%

Market context

Why it moved

NVAX edged slightly lower amid a broader risk-off environment driven by escalating U.S.-Iran geopolitical tensions and a global chip-led market selloff, with no specific catalyst strong enough to offset the general market pressure on the stock.

FacebookNexus AlertPharosinvFacebookStocktwits

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Novavax closed essentially unchanged as broader market headwinds — including a tech-led selloff driven by AI spending concerns and escalating U.S.-Iran tensions — weighed on sentiment across healthcare and biotech. The stock trades well below its February highs, when shares surged 17% on a strong Q4 earnings beat and optimism around Sanofi's flu-COVID combination shot and the Pfizer Matrix-M licensing deal. With 2026 guidance of $230–$270M in adjusted revenue, investors continue to monitor Sanofi's first full commercial cycle for Nuvaxovid and pipeline progress in C. difficile, shingles, and RSV.

-0.3641

July 15, 2026Novavax tumbled over 5% as broader healthcare sector weakness and macro headwinds weighed on the biotech. The XLV healthcare ETF declined on the day amid earnings pressure from major sector constituents, while Novavax faces a cautious analyst consensus with a $9 price target and a 'Hold' rating as it transitions to a royalty-driven model anchored by its Sanofi partnership. Analysts note that while Q1 2026 revenue of $140M and full-year guidance of $230–$270M reflect progress, the seasonal COVID market remains niche and meaningful upside requires further clinical and commercial differentiation—particularly from its Matrix-M licensing deals and pipeline candidates in C. diff and combination vaccines.

-5.4994

July 14, 2026Novavax shares declined amid a broad market selloff driven by renewed U.S.-Iran military tensions that sent oil prices surging and dampened risk appetite across equities. The broader healthcare sector (XLV) also closed lower, while Moderna fell nearly 2% on the same session, reflecting weakness across vaccine-related names. Despite the macro headwinds, the biotech sector remains a focus for investors, with Goldman Sachs and Jim Cramer both flagging biotech as a standout group with strong M&A tailwinds — a theme that could benefit Novavax given its Pfizer Matrix-M adjuvant licensing deal and ongoing pipeline efforts.

-4.5016

July 11, 2026Novavax edged lower on modest volume as the stock continues to trade near analyst consensus price targets of $9, reflecting a cautious market stance on its ongoing transition to a royalty-driven model. While the broader biotech sector has been quietly outperforming — with XLV hitting record highs and Jim Cramer calling biotech 'the hottest group in the market' — Novavax has yet to recapture meaningful momentum, weighed down by a narrow COVID vaccine portfolio and persistent questions around whether its Matrix-M licensing and Sanofi partnership revenue can sustain long-term growth.

-0.7447

July 10, 2026Novavax edged modestly higher, closing up about 0.5%, even as the broader healthcare sector (XLV) and S&P 500 faced headwinds from geopolitical volatility tied to renewed U.S.-Iran military exchanges. Investor attention remains focused on Novavax's ongoing transition to a royalty-driven business model, with analysts recently lifting their consensus price target to $9 and noting that the Pfizer Matrix-M licensing deal and Sanofi flu-COVID partnership are key near-term catalysts. Jim Cramer's bullish call on biotech M&A, citing a more favorable FDA backdrop, has added a tailwind to sector sentiment that could benefit Novavax given its attractive IP portfolio and speculation around acquisition potential.

0.5348

July 9, 2026Novavax shares declined modestly, pressured by a broad risk-off session after President Trump declared the U.S.-Iran ceasefire 'over,' sending oil prices surging over 5% and triggering a market-wide selloff. The healthcare sector held up better than most, buoyed by ongoing M&A optimism — Jim Cramer recently called biotech 'the hottest group in the market' — but NVAX remains rangebound near analyst consensus targets of ~$9, as investors weigh its pivot to a royalty-driven model anchored by the Sanofi and Pfizer Matrix-M licensing deals against a niche COVID vaccine market.

-1.1628

July 8, 2026Novavax shares edged higher, closing with a modest gain as the healthcare sector continues its recent winning streak — XLV closed near its 52-week high — providing a supportive backdrop for biotech names. Jim Cramer's bullish call on biotech M&A on July 6, citing a more favorable FDA regulatory environment, added broader sector tailwinds. For Novavax specifically, investor focus remains on its royalty-driven transition anchored by the Sanofi partnership, with full-year guidance of $230–$270M (mostly royalties) and a cash runway into 2028. Analyst consensus sits near $9, reflecting caution around the niche COVID vaccine market and dependence on licensing revenue for sustainable growth.

1.1765

July 7, 2026Novavax shares fell as healthcare stocks broadly underperformed, with sector heavyweights like Pfizer, Johnson & Johnson, and AbbVie all declining on the day while tech and semiconductors rallied. The pullback comes despite Novavax's underlying story remaining intact — the company's Q1 2026 earnings beat, driven by surging licensing and royalty revenue tied to its Matrix-M adjuvant deal with Pfizer, had bolstered investor sentiment in May. With the broader healthcare sector under pressure and macro attention shifting toward upcoming Fed minutes and Q2 earnings season, Novavax drifted lower on below-average volume.

-4.0041

Simply Wall Street · July 18, 2026Novavax (NVAX) Stock Still Looks Pricey As Sales Struggle To Support ItMoomoo · July 7, 2026BofA Securities Maintains Novavax(NVAX.US) With Sell Rating, Maintains Target Price $8pharmaphorum · June 24, 2026Activist investor renews its criticism of NovavaxPharmaceutical Executive · June 16, 2026Novavax's Strategy Across Commercial, R&D, and PartnershipsStockStory · May 8, 2026Why Novavax (NVAX) Stock Is Trading Up TodayPR Newswire · May 6, 2026Novavax Reports First Quarter 2026 Financial Results and Operational HighlightsInvesting.com · April 21, 2026H.C. Wainwright reiterates Novavax stock rating on vaccine studyThe Business Journals · April 8, 2026Investor calls for Novavax to slash costs, cut board as vaccine sales disappoint
Benzinga · May 28, 2026U.S. FDA Advisers Vote In Favor Of Recommending Covid Vaccines Target JN.1 Lineage XFG Variant For 2026-27 Campaign
Benzinga · May 11, 2026Hantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax Climb
Benzinga · May 8, 2026What's Going On With Novavax Stock On Friday?
Benzinga · May 6, 2026TD Cowen Maintains Hold on Novavax, Raises Price Target to $9
Benzinga · May 6, 2026Why Novavax Stock Is Trading Higher On Wednesday?
Benzinga · May 6, 2026Novavax Q1 2026 Earnings Call Transcript
Mt Newswire · May 6, 2026Novavax Shares Rise After Narrower-Than-Expected Q1 Net Loss
Benzinga · May 6, 2026Novavax Affirms FY2026 Sales Guidance of $230.000M-$270.000M vs $393.277M Est

Peers

S&P 500SPX · $7,457.69-1.01%Moderna, Inc.MRNA · $61.82-2.11%Pfizer Inc.PFE · $25.05-0.36%BioNTech SEBNTX · $91.48-0.09%Johnson & JohnsonJNJ · $253.04+1.23%AstraZeneca PLCAZN · $168.90-0.23%GSK plcGSK · $51.76-1.91%SanofiSNY · $44.66+1.02%Emergent BioSolutions Inc.EBS · $7.63-0.78%Inovio Pharmaceuticals, Inc.INO · $1.120.00%Ocugen, Inc.OCGN · $1.36-0.73%BioCryst Pharmaceuticals, Inc.BCRX · $9.29+2.03%